

This press release is an English translation of a Japanese-language press release. The official language of this press release is Japanese, and the Japanese version takes precedence over the English version in terms of content and interpretation.

<Press Release>

July 23rd, 2024

**Chordia wins the Minister of Education, Culture, Sports,  
Science and Technology Award at the Japan Startup Awards 2024.**

Chordia Therapeutics Inc. (“Chordia”), a biotech company engaged in the research and development of novel therapies for cancer, was awarded the Minister of Education, Culture, Sports, Science and Technology Award at the "Japan Startup Awards 2024" ceremony for its outstanding contribution to the effort on commercialization of research results as a university-based startup.



(Left: Daisuke Morishita, CSO; Right: Masahito Moriyama, Minister of Education, Culture, Sports, Science and Technology)

As a start-up spin-out from major companies, we are developing new anti-cancer drugs based on academic seeds discovered by Kyoto and Miyazaki Universities, with support from AMED and public-private fund iCAP. In 2020, MALT1 inhibitor CTX-177 (ONO-7018) was out-licensed to Ono Pharmaceutical Company Ltd. and received an upfront payment of ¥800 million and a first development payment of ¥2.5 billion. In addition, we are entitled to receive up to 49.6 billion yen in milestone payments based on future development progress and sales, as well as tiered royalties in the high single to low double digits based on worldwide sales. Through industry-government-academia collaborative research, we aim to create novel anti-cancer drugs and new

## Chordia Therapeutics Inc.

26-1, Muraoka-Higashi 2-chome, Fujisawa, Kanagawa 251-0012, Japan

ir@chorditherapeutics.com



therapeutic options for cancer patients who still lack adequate treatment and contribute to the drug discovery ecosystem in Japan.



### **About the Japan Startup Awards**

The Japan Startup Awards is a system to honor and celebrate entrepreneurs and startups who have created impactful new businesses that will serve as role models for the next generation. The purpose of the award is to promote the importance of taking on challenges and the social recognition of entrepreneurs in general among people who aspire to start their own businesses and society at large, thereby raising awareness of entrepreneurship in society.

### **About Chordia Therapeutics**

Chordia is a clinical-stage biotech company based in Fujisawa, Kanagawa, Japan, developing novel cancer therapies. Chordia's lead asset, CLK inhibitor CTX-712, is currently in Phase 1 clinical study in Japan and Phase 1/2 clinical study in the US. CTX-712 potentially targets vulnerabilities in cancer and could benefit patients with various types of cancer. In addition to CTX-712, Chordia is researching several preclinical assets, including CTX-439, a CDK12 inhibitor, which might be effective in cancers with specific abnormalities, as well as GCN2 inhibitors.

Established: November 2017  
Address: 26-1, Muraoka-Higashi 2-chome, Fujisawa,  
Kanagawa 251-0012, Japan  
Representative: Hiroshi Miyake, Representative Director  
Website: <https://www.chorditherapeutics.com/en/>

For more information, please contact to IR: [ir@chorditherapeutics.com](mailto:ir@chorditherapeutics.com)